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Abstract
Through the implementation of national bowel cancer screening programmes we
have seen a three-fold increase in early pT1 colorectal cancers, but how these
lesions should be managed is currently unclear. Local excision can be an
attractive option, especially for fragile patients with multiple comorbidities, but it
is only safe from an oncological point of view in the absence of lymph node
metastasis. Patient risk stratification through careful analysis of histopathological
features in local excision or polypectomy specimens should be performed
according to national guidelines to avoid under- or over-treatment. Currently
national guidelines vary in their recommendations as to which factors should be
routinely reported and there is no established multivariate risk stratification
model to determine which patients should be offered major resectional surgery.
Conventional histopathological parameters such as tumour grading or
lymphovascular invasion have been shown to be predictive of lymph node
metastasis in a number of studies but the inter- and intra-observer variation in
reporting is high. Newer parameters including tumour budding and poorly
differentiated clusters have been shown to have great potential, but again some
improvement in the inter-observer variation is required. With the
implementation of digital pathology into clinical practice, quantitative
parameters like depth/area of submucosal invasion and proportion of stroma can
be routinely assessed. In this review we present the various histopathological risk
factors for predicting systemic spread in pT1 colorectal cancer and introduce
potential novel quantitative variables and multivariable risk models that could be
used to better define the optimal treatment of this increasingly common disease.
Key words: Early colorectal cancer; Bowel cancer screening; Local resection; Major
resection; Morphological risk factors; Conventional histopathology parameters; Novel
histopathology parameters; Risk stratification models; Digital pathology
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Core tip: Since the implementation of national bowel cancer screening programmes we
have seen a three-fold increase in early colorectal cancers but how these lesion should
surgical managed is currently unclear. Conventional histopathological parameters such
as tumour grading or lymphovascular invasion have been shown to be predictive of
lymph node metastasis but the inter- and intra-observer variation in reporting is
significant. This review present the various conventional histopathological risk factors
for predicting systemic spread in pT1 colorectal cancer and introduces novel quantitative
variables and multivariable risk models that could be used to better define the optimal
treatment of this increasingly common disease.
Citation: Brockmoeller SF, West NP. Predicting systemic spread in early colorectal cancer:
Can we do better? World J Gastroenterol 2019; 25(23): 2887-2897
URL: https://www.wjgnet.com/1007-9327/full/v25/i23/2887.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i23.2887
INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancers worldwide[1,2]. It is the
third most common cause of cancer death in the United Kingdom and the United
States  in  both  females  and  males[1].  Through  the  implementation  of  national
population screening[3]  like  the  United Kingdom National  Health  Service  Bowel
Cancer Screening Programme (NHS BCSP) we have observed a three-fold increase in
early CRC (stage pT1) from 5% to 17%[4]. Early CRC is defined as the “invasion of
neoplastic glandular epithelial cells through the muscularis mucosae into the sub-
mucosa of the bowel wall but not beyond”[5].
Currently it is unclear as to how pT1 CRC should be optimally managed. Major
bowel resection can be performed, however, this is associated with a significant risk of
post-operative mortality, especially in elderly patients, and also morbidity including
permanent  colostomy  formation,  sexual  and  genitourinary  problems,  and  low
anterior  resection syndrome.  Internationally,  postoperative  mortality  rates  vary
markedly, largely depending on background comorbidity in the population. Local
excision of the tumour and avoidance of major surgery is an attractive option for
patients with rectal cancer or significant comorbidity, but this is only safe from an
oncological  viewpoint  in  the  absence  of  lymph  node  metastasis  (LNM)[6,7].  It  is
therefore  important  that  when  deciding  whether  major  bowel  surgery  or  local
excision should be performed, the postoperative mortality and lymph node metastasis
risk are accurately estimated to inform the decision. Approximately 10%-15% of all
pT1 CRC have LNM at the time of primary diagnosis with pedunculated pT1 CRC
having an even lower risk (3% to 7% in the Asian population). Despite this major
bowel resection rates in pT1 CRC can be as high as 76%, meaning that many patients
are potentially exposed to unnecessary risk[8-11].
When a local excision (including polypectomy) is performed for pT1 CRC, patient
risk stratification is undertaken by histopathologists through careful analysis of the
specimen to determine the risk of LNM. The detailed macroscopic and microscopic
evaluation of the specimen produces a large amount of information to guide further
treatment. Routine information that is generally collected internationally includes the
type of tumour, differentiation grade, TNM stage, level of invasion, number of lymph
nodes  involved,  lymphatic  invasion  status,  venous  invasion  status,  perineural
invasion status and resection margin status[12]. Currently various national guidelines
differ  in  their  recommendations as  to  which histopathological  factors  should be
reported and used to determine the risk of LNM and therefore use of major surgery,
and there is no established multivariate risk stratification model. The classification of
some factors  is  also  not  performed according  to  an  international  standard with
various  systems in  use.  This  review will  present  and discuss  the  various  histo-
pathological risk factors that can be used to predict systemic spread in in pT1 CRC
and introduce potential novel quantitative variables and multivariable risk models
that could be used to better define the optimal treatment of this increasingly common
disease.
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LITERATURE SEARCH
Literature searching was performed in PubMed (https://www.ncbi.nlm.nih.gov
/pubmed) for the following keywords: “lymph nodes”, “lymph node metastasis”,
“T1” and “pT1” combined with “colorectal cancer”. Articles published between July
2004 and January 2019 were reviewed. In addition, manual cross-referencing was
performed and further relevant papers published before 2007 identified through
review articles. Inclusion criteria for studies included publication in English, use of at
least  100 patients  and availability  of  LNM status.  Studies  were excluded if  neo-
adjuvant therapy was used due to the potential effect on tumour staging.
CONVENTIONAL HISTOPATHOLOGICAL PARAMETERS
Histological tumour type
The majority of CRCs are adenocarcinoma but specific histological variants including
cribriform or micropapillary adenocarcinoma have been reported in case series to
have a higher rate of  LNM in early CRC[13],  and may be used to indicate further
treatment in margin negative local excisions[14]. Mucinous adenocarcinomas (> 50% of
the tumour area composed of extracellular mucin), signet ring cell adenocarcinomas
(> 50% of  the area composed of  signet  ring cells)  and medullary carcinomas are
associated with deficient mismatch repair (dMMR), which has a better prognosis
when compared to  cases  with  proficient  mismatch repair.  Yet  in  the  absence  of
deficient mismatch repair, these histological subtypes are associated with a poorer
prognosis  than  conventional  CRC and further  treatment  may be  indicated.  The
importance of routine mismatch repair immunostaining is detailed below.
Tumour differentiation grading
Poor tumour differentiation has been shown in numerous studies, including meta-
analyses, to be significantly associated with poorer survival[15-17] and prediction of
LNM in early CRC[7,18]. Poor differentiation is primarily based on the architecture of
the tumour and the hallmark is the absence of any tubular formation or irregularly
folded,  distorted and often small  tubules.  Tumour differentiation is  a  subjective
parameter and grading may vary between assessors. Currently the WHO grading
system proposes a four tier classification including: Grade 1 (well differentiated),
grade 2  (moderately  differentiated),  grade 3  (poorly  differentiated)  and grade 4
(undifferentiated)[5]. An improvement in inter-observer agreement can be achieved
through compressing this system into two grades, i.e., well/moderate differentiation
vs poor differentiation[19]. This has been routinely adopted in the United Kingdom on
the basis that poor differentiation is an important high-risk feature in early CRC. With
the  implementation  of  digital  pathology  into  routine  clinical  practice,  tumour
differentiation grading could be further improved by the implementation of auto-
mated algorithms to reduce the subjectivity of pathologist assessment[20-22].
For local excision specimens, there is currently uncertainty as to whether grading
should be based on the predominant or worst area of differentiation, as most pub-
lished studies have not specified how poor differentiation was defined. To avoid the
risk of under-treatment in early CRC, the Royal College of Pathologists re-commend
grading on the worst area in local excision specimens until further data are avai-
lable[19]. In contrast, a major resection specimen is graded based on the predominant
area of the tumour.
Whilst poor differentiation is generally accepted to be a poor prognostic feature, an
exception in which it is associated with a more favourable stage-adjusted prognosis is
in patients with dMMR, seen in 12%-15% of all cases[23,24]. Most dMMR cases are due to
somatic epigenetic silencing of the MLH1 gene but a minority of cases are due to
Lynch syndrome. From the current literature it  is  unclear if  patients with poorly
differentiated pT1 dMMR CRCs have a lower risk of LNM than poorly differentiated
pT1 CRCs without dMMR. However, given the rarity of metastatic disease in dMMR
CRC it  is  likely  that  poor  differentiation is  only  an adverse  factor  in  cases  with
proficient mismatch repair. Further evidence is required to confirm this hypothesis.
Mismatch  repair  immunohistochemistry  or  alternative  technologies  including
microsatellite instability testing should therefore be considered mandatory when
determining LNM risk in local excision specimens.
Venous, lymphatic and perineural invasion
The presence of submucosal lymphatic invasion[7,17,25,26] [relative risk (RR) = 5.2, 95%
confidence interval (CI): 4.0-6.8[7] ] and to a much lesser extent venous invasion (RR =
2.2; 95%CI: 1.4 -3.2[7]) and perineural invasion[27] have been shown to be some of the
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strongest predictors of LNM in early CRC. It is therefore important to carefully assess
for their presence and report these factors separately rather than stating the presence
“lymphovascular  invasion”  for  example.  The  location  of  the  deepest  point  of
involvement (either intramural or extramural)  should be specified as this is  also
prognostic[28]. In the context of a local excision, the deepest point visible will usually
be intramural. Lymphatic invasion is well recognised to be subjective with significant
rates of inter-observer variation[29]. This can be caused by difficulties distinguishing
lymphatics  from  venules,  retraction  artefacts,  tumour  budding  and  poorly  di-
fferentiated clusters[29,30].  In  cases  of  doubt,  D2-40 immunohistochemistry can be
helpful  to confirm the presence of  a lymphatic  channel  and elastin stains can be
helpful  to  identify  veins[25].  The  use  of  such  ancillary  stains  has  been  shown to
significantly improve the inter-observer agreement[31].
Resection margin status
In  polypectomy/local  excision  specimens,  the  status  of  the  resection  margin  in
conjunction with other high risk histopathology factors determines the risk of local
recurrence. Tumours which are present at the resection margin or within the dia-
thermised zone should be considered for further treatment regardless of high risk
factors. In cases where the invasive tumour extends to the peripheral resection margin
only, a repeat endoscopy and further local excision should be considered[19].
There is currently significant controversy about the degree of risk in cases where a
tumour extends close to the deep resection margin (1 mm or less) but does not directly
involve it. Within the NHS BCSP, the recently revised pathological reporting guidance
has maintained 1 mm as the optimal cut-off to define margin involvement in order to
reduce the risk of incomplete resection, despite the risk that this strategy will lead to a
higher rate of major bowel surgery. Despite this guidance, in the absence of any other
high-risk histopathology features, local re-excision may be a reasonable treatment
option[11,32,33].
Level of submucosal invasion
Depending on the shape of the lesion (pedunculated or non-pedunculated), and the
status  of  the  muscularis  mucosa  (identifiable  or  non-identifiable),  different
classification systems may be used to define the level of submucosal invasion. A
qualitative assessment of sessile lesions was initially proposed by Kudo et al[34] which
separated the submucosa into thirds: sm1 (superficial); sm2 (middle); and sm3 (deep).
Invasion into sm3 has been associated with a higher risk of LNM when compared to
invasion confined to sm1/sm2 (RR = 3.6, 95%CI: 1.3-9.8)[7]. This method was further
subsequently modified into a semi-quantitative system by Kikuchi (sm1: Invasion up
to  0.2-0.3  mm;  sm2:  Intermediate  invasion;  sm3:  Invasion  near  the  muscularis
propria)[35]. A third quantitative measurement with a clear cut-off defining the levels
as sm1: Up to 0.5mm; sm2: 0.5-1.0 mm; sm3: Beyond 1.0 mm[36]. A second classification
system was proposed by Haggitt for pT1 CRC with a polypoid shape, which assesses
the depth of invasion into four levels, with level four invasion described as an adverse
factor[37].
Several issues arise when attempting to apply these two classification systems in a
routine  clinical  setting.  Firstly,  the  received  sample  can  become  fragmented  or
suboptimally orientated on histological sections meaning that accurate assessment is
not possible. To apply the Kudo system, the muscularis propria needs to be visible
which is not usually present in local excisions (with the exception of full thickness
transanal resection specimens). Without the muscularis propria indicating that the full
thickness of the submucosa is included, accurate division of the submucosa into thirds
is impossible. Haggitt classification can also be difficult to apply in poorly orientated
specimens or polyps that are lacking a clear stalk. These limitations and difficulties
show the need for better alternative measures that reply on quantitative parameters.
NOVEL HISTOPATHOLOGICAL PARAMETERS
Depth of submucosal invasion
Studies, in particular of Japanese populations, have identified the absolute depth of
submucosal invasion as an important quantitative factor for predicting lymph node
metastasis[38,39]. Ueno et al[11] proposed that the absolute depth of invasion beyond the
muscularis mucosa and the width of the invasive tumour are more objective para-
meters than the conventional factors described above[11,17].  On univariate analysis,
submucosal invasion ≥ 1 mm was predictive for LNM in pT1 CRC (RR = 5.2, 95%CI:
1.8-15.4)[7].
The current guidelines from the Japanese Society for Cancer of  the Colon and
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Rectum recommend major resection if the cancer has an involved deep margin or if
one of the following high risk factors is present: poor differentiation, signet-ring cell
carcinoma, mucinous carcinoma, depth of invasion > 1000 µm, vascular invasion or
budding  G2/G3[14].  Interestingly  a  study in  the  Japanese  population  found that
submucosal invasion depth > 1000 µm alone would lead to approximately 80% of
malignant  polyps being treated with laparotomy[39].  This  approach has not  been
routinely adopted in western populations as it would cause a significant increase in
the major resection rate in patients with a significantly higher risk of post-operative
mortality. In addition, there is only limited data on the prediction of LNM according
to the absolute depth of submucosal invasion in western populations[40].
Area of submucosal invasion
Three dimensional histological reconstructions of the large intestinal submucosa has
demonstrated that the number and size of blood and lymphatic vessels does not
increase towards the base of  the submucosa as expected[41,42].  There are a greater
number of  vessels  in sm1 and the vessels  are largest  in sm2, suggesting that the
absolute depth of submucosal invasion may not be the most important parameter.
Pilot studies in a western populations have suggested that the width of the cancer
(cut-off 11.5 mm; P = 0.001) and the area of submucosal invasion (cut-off 35 mm2; P <
0.001)  were  significantly  associated with  the  risk  of  LNM and showed superior
prediction when compared to the depth of invasion[40]. Taken together, it is highly
likely that the absolute area of submucosal invasion in sm1/sm2 where the majority
of vessels are located is the best predictor of LNM. With the routine adoption of
digital pathology, measuring the area of submucosal invasion is now readily feasible
(Figure 1).
Tumour budding
The predictive value of tumour budding for LNM has been demonstrated for various
cancers[43-46], but implementation into routine guidelines has been hindered by a lack
of practical guidance on assessment. Multiple different systems are described in the
literature leading to confusion over which system should be used[47].  Recently an
international consensus group agreed the definition of budding as “a single cancer
cell or a cell cluster of up to four tumour cells”[48] as well as detailing the practical
steps that should be taken to evaluate this marker (Figure 2).  This led to the im-
plementation of tumour budding as an additional prognostic factor in the eighth
edition of the Union for International Cancer Control's (UICC's) TNM classification.
Tumour budding has been included in the College of American Pathologists (CAP)
guidelines but not yet as a core factor in the UK guidelines until sufficient evidence of
reproducibility and its role in patient risk stratification exists[19]. Nevertheless some
studies have shown that the inter-observer variation in tumour budding is improved
by  the  international  consensus  definition,  although  further  studies  in  western
populations are needed given that most of the large studies to date have been per-
formed in Asian populations.
Poorly differentiated clusters
A new emerging  risk  factor  for  LNM in  pT1  CRC is  the  presence  of  poorly  di-
fferentiated clusters (PDC), which are defined as “malignant clusters with five or
more cells lacking glandular differentiation”[49,50] (Figure 2). Studies have shown that
the presence of PDC is a strong predictor of LNM with greater reproducibility than
tumour differentiation or budding in a study of 3,556 pT1 CRC [OR = 3.3 (95%CI: 2.6-
4.1) P < 0.0001]. Further validation work is now required to confirm the importance of
PDC in early CRC and define the optimal risk cut-offs in addition to clear practical
guidance on the method of assessment[49].
Proportion of stroma
An emerging quantitative prognostic factor is the proportion of stroma within the
overall tumour area[51]. It has been shown in a number of different cancers, including
CRC, that a greater proportion of stroma is a poor prognostic factor[52-55]. The pro-
portion of stroma can be subjectively estimated by the tumour stroma ratio[56]  or
accurately quantitated by cell density measurements[54]. It is thought that in CRC the
high stroma group correlates with CMS4 consensus molecular subtyping, with both
groups accounting for  around 25% of  cases  with the poorest  prognosis[57-59].  The
prediction of LNM in pT1 CRC according to the proportion of stroma is as yet un-
known but studies are ongoing.
Tumor immunology
The quantitation of the total number of tumour infiltrating lymphocytes has been
shown to correlate with prognosis in CRC and other cancer types[60-62]. A study of 29
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Figure 1
Figure 1  An example showing measurement of the area of submucosal invasion on a digital slide of a pT1
colorectal cancer (green area). The position of the destroyed muscularis mucosae has been estimated. The scale
bar signifies 2 mm.
early  stage  CRC  (stage  I  and  II)  showed  that  the  combination  of  CD8(+)  plus
CD45RO(+)  cells  could  be  predictive  for  tumour  recurrence  and survival[63].  An
increase in  specific  lymphocyte populations has been shown to strongly predict
prognosis  in  CRC.  The  best-reported  system  in  the  recent  literature  is  the  Im-
munoscore®,  which is  generated on the basis  of  CD3 and CD8 expression in  the
tumour[64-66]. Automated algorithms to assess the number of lymphocytes are currently
being explored. Again, the prediction of LNM in pT1 CRC according to tumour im-
munology is as yet unknown.
META-ANALYSIS OF HISTOPATHOLOGICAL PARAMETERS
A meta-analysis  from 2011 included 17 studies with a total  of  3621 patients  and
showed that  the presence of  lymphatic  invasion (RR = 5.2,  95%CI:  4.0-6.8),  high
tumour budding (RR = 5.1, 95%CI: 3.6-7.3), submucosal invasion ≥ 1 mm (RR = 5.2,
95%CI: 1.8-15.4), and poor differentiation (RR = 4.8, 95%CI: 3.3-6.9) were associated
with a higher risk of LNM in pT1 CRC on univariate analysis[7]. Another fixed-effects
meta-analysis included 76 studies and showed that lymphatic invasion (OR = 8.62)
was the strongest factor,  followed by tumour depth (pT2 vs  pT1; OR = 2.62) and
tumour differentiation (OR = 2.38) in predicting LNM[26]. In a subset analysis, poor
differentiation at the invasive front (OR = 6.08) and tumour budding (OR = 5.82) were
the most predictive in rectal cancer[26]. A meta-analysis from 2013 included 23 studies
with 4510 patients and demonstrated similar findings, with a greater risk of LNM in
pT1 CRC with a depth of submucosal invasion of > 1 mm (OR = 3.87, 95%CI: 1.50-
10.00, P = 0.005), lymphovascular invasion (OR = 4.81, 95%CI: 3.14-7.37, P < 0.00001),
poor differentiation (OR = 5.60, 95%CI: 2.90-10.82, P < 0.00001) or tumour budding
(OR = 7.74, 95%CI: 4.47-13.39, P  < 0.001)[17].  Finally, a meta-analysis in early CRC
included 41 studies with 10137 patients and showed a strong association between the
presence of tumour budding and risk of LNM in pT1 CRC (OR = 6.44; 95%CI: 5.26-
7.87; P < 0.0001)[67].
MULTIVARIATE RISK STRATIFICATION MODELS
The univariate analyses described above have identified a number of conventional
and novel histopathological  risk factors for LNM in pT1 CRC. To date,  very few
studies have proposed multivariate risk prediction models and currently there is no
single risk stratification model used internationally. Ueno et al[11] demonstrated that
the best risk multivariate prediction model in a cohort of 251 cases included poor
differentiation (OR = 2.9;  95%CI:  1.2-7.4;  P  = 0.023),  vascular invasion (OR = 2.7;
95%CI: 1.1-7.0; P = 0.039), tumour budding (OR = 3.7; 95%CI: 1.4-9.9; P = 0.008) and
width of submucosal invasion (≥ 4000 μm)[11].  Another study of 140 cases used a
logistic regression analysis and built an algorithm based on lymphatic invasion (OR =
1.45, P < 0.05), absence of lymphocyte infiltration (OR = 16.6, P = 0.016), cribriform-
type structural atypia (OR = 3.7; P < 0.05), venous invasion (OR = 3.26, P < 0.05), and
depth of invasion (cut-off > 2 mm; OR = 1.45, P < 0.05)[68]. Lymphocyte infiltration was
investigated in the invasive area of submucosal carcinoma and classified as either
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Figure 2
Figure 2  An example of tumour budding (blue arrows) and poorly differentiated clusters (yellow arrows) at
the invasive edge of a pT1 colorectal cancer. The scale bar signifies 100 µm.
negative (no or little infiltration) or positive (follicular structures or infiltration by
more lymphocytes than the number of tumour cells).
A larger retrospective study of 806 cases showed that independent predictors of
LNM in multivariate analysis were: depth of submucosal invasion ≥ 1000 µm (OR =
5.56; 95%CI: 2.14-19.10) and high-grade budding (OR = 3.14; 95%CI: 1.91-5.21). High-
grade budding was defined as five or more buds per high power field (0.95 mm2). The
study  proposed  a  three-tier  risk  classification  system  based  on  the  depth  of
submucosal invasion and budding: high-risk with a depth of submucosal invasion ≥
1000 µm and high-grade budding, intermediate-risk with a depth of submucosal
invasion ≥ 1000 µm and low-grade budding, and low-risk with a depth of submucosal
invasion < 1000 µm. Additional factors for used to subclassify the intermediate risk
group further were lymphovascular invasion and differentiation grade[69].
A recently published study proposed a risk stratification model for pedunculated
pT1 CRC (3% to 7% LNM rate in Asian populations)[9,10,39,69]  and investigated the
following six factors: tumour differentiation; submucosal invasion depth by Haggitt
classification; lymphovascular invasion; tumour budding; PDCs; and the condition of
the muscularis mucosae[70]. Tumour budding and PDC were defined and graded as
above but assessed in a 0.785 mm2 field (grade 1: 0-4; Grade 2: 5-9; Grade 3: 10 or
more). The status of the muscularis mucosa was classified as Type A: Shattered but
aligned muscularis mucosa or Type B: Incompletely or completely disrupted mu-
scularis mucosae. The authors ultimately recommended a new model including the
following  four  risk  factors:  lymphovascular  invasion;  Haggitt  level  4  invasion;
muscularis  mucosae  type  B  (incompletely  or  completely  disrupted);  high grade
PDCs/tumour budding (both grade 2-3).  High-grade tumour budding and high-
grade PDC were grouped together as “any kind of positive budding”. The model had
a sensitivity of 83.8% and specificity of 70.3% for predicting LNM (area under the
curve value of 0.83), and would classify 32% of all cases in the high-risk group, 68% in
the low risk group and miss 1.3% of all LNM.
Unfortunately the majority of these studies include retrospective series with small
numbers of patients. Due to the 10%-15% rate of LNM in pT1 CRC, only a limited
number of events are present leading to limited data in both Western and Asian
populations. Well-designed prospective cohort studies are urgently needed to define
robust international  standards[49,69].  Ultimately a validated multivariate risk stra-
tification model including both clinical and histopathological factors could be used to
define prognosis in a similar way to that already developed for breast cancer.
DISCUSSION
In this review we have summarised the main conventional histopathological risk
factors  for  LNM in pT1 CRC in addition to  a  number of  novel  factors  that  have
recently  been  proposed.  It  is  well  recognised  that  parameters  including  lym-
phovascular invasion, poor differentiation, and depth of submucosal invasion are
significantly  correlated  with  an  increased  risk  of  LNM.  Unfortunately,  lymph-
ovascular invasion and tumour differentiation grading show high levels of inter-
observer variation, which limits their clinical usefulness. Univariate markers for LNM
in pT1 CRC should therefore be interpreted with caution when deciding whether to
proceed with major bowel resection after local excision due to the significant risks of
major morbidity and mortality.
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With the routine implementation of digital pathology into clinical diagnostics[20-22],
novel histopathological markers including the absolute depth of invasion, area of
submucosal invasion and proportion of stroma can now be easily measured. Due to
the quantitative nature of these parameters, it is likely that they are considerably more
reproducible than the traditional subjective parameters. However, their evaluation
can take a considerable amount of time to perform manually, hence there is a clear
role for artificial intelligence, which is also likely to improve the reproducibility of
con-ventional and novel risk factors.
Multivariate  risk  stratification models  need to  be  developed and validated to
optimise the management of pT1 CRC. In the future, artificial intelligence on digital
pathology slides could be applied to compare different multivariate risk stratification
models to identify the optimal way to accurately predict LNM[71]. This will should
reduce the inaccuracy associated with relying on individual subjective markers and
has the potential to further refine the group at highest risk of LNM and therefore
reduce the overall number of patients exposed to the risks of major bowel resection.
By combining the histopathological data with molecular data, patient data and treat-
ment data, a personalised risk stratification model could be created with the aim of
determining the optimal treatment pathway for individual patients[49].
CONCLUSION
In this review we present the various histopathological risk factors for predicting
systemic spread in pT1 colorectal cancer and introduce potential novel quantitative
variables and multivariable risk models that could be used to better define the op-
timal treatment of this increasingly common disease.
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